International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Emerging Trends in Antibiotic Resistance Among Uropathogens Causing Urinary Tract Infections in India: A Comprehensive Review of Recent Epidemiological Data

Dr Mohammed Khaja Moinudeen[1], Mr Bhavsar Dhruv Nishant[2], Ms Phadtare Aditi Ganesh[3], Dr Durgam Varsha[4], Dr Sai Mouli Krishna Garre[5]

[1]MBBS, Al Falah School Of Medical Science And Research Center
[2]MBBS Intern, Aarupadai Veedu Medical College And Hospital
[3]MBBS Intern, Krishna Institute Of Medical Sciences
[4]MBBS, Sri Venkateshwaraa Medical College Hospital And Research Centre, Puducherry
[5]MBBS, Gsl Medical College, Rajamahendravaram, A.P

Abstract

Urinary tract infections (UTIs) represent one of the most common bacterial infections globally, with a particularly high burden in India due to factors such as overcrowding, poor sanitation, and widespread antibiotic misuse. This review synthesises recent data on the prevalence, common pathogens, and antibiotic resistance patterns of uropathogens in Indian settings, with a focus on community-acquired and hospital-associated cases. *Escherichia coli* remains the predominant isolate (typically 50-70%), followed by *Klebsiella pneumoniae* (15-25%) and *Pseudomonas aeruginosa*. High rates of resistance to first-line agents like fluoroquinolones, third-generation cephalosporins, and cotrimoxazole are observed, alongside rising carbapenem resistance (often exceeding 20% in *E. coli* and *K. pneumoniae* in community settings). Extended-spectrum beta-lactamase (ESBL) production is prevalent (30-60% in many studies). Enhanced surveillance, stewardship programs, and development of region-specific guidelines are urgently needed.

Introduction

A UTI (Urinary Tract Infection) is a bacterial infection in any part of your urinary system, which includes the kidneys, bladder, ureters, and urethra. Urinary tract infections affect millions annually, particularly women, the elderly, and immunocompromised individuals.

Early initiation of appropriate antibiotics within 48 hours of fever onset decreases the risk of renal scarring in the future. Antibiotic resistance in UTIs, which has emerged as a major threat, complicating treatment, increasing healthcare costs, and contributing to higher morbidity.

Risk factors for resistant UTIs include prior antibiotic exposure, hospitalization, diabetes, and catheterization. Regional variations exist, with higher MDR in urban and northern areas. In India, the epidemiology is influenced by socioeconomic determinants, including limited access to clean water, high

population density, and unregulated over-the-counter antibiotic sales.0233 These factors drive the selection and spread of resistant strains.

Mechanisms most relevant to Uropathogens include ESBL production (hydrolysing third-generation cephalosporins), carbapenemases (KPC, NDM, OXA-48-like enzymes), efflux pumps, porin loss, target modifications (quinolone resistance), and plasmid-mediated transmission of resistance genes. Molecular epidemiology has shown the rapid dissemination of plasmidborne carbapenemases, notably NDM variants, across the Indian subcontinent.

This study reviews the epidemiology of rise in antimicrobial resistance among uropathogens and the deleterious effects of using empirical therapy in the preliminary stages of the infection.

Methods

This narrative review compiled peer-reviewed literature from PubMed and other databases, focusing on Indian studies published in the last decade, with emphasis on post-2020 data. Inclusion criteria encompassed original research and reviews reporting culture-positive UTI isolates, antibiograms, and resistance mechanisms like ESBL and carbapenemases. Key pathogens and resistance percentages were aggregated qualitatively due to methodological heterogeneity across studies. Prevalence and resistance tables were constructed from representative datasets.

Results

Prevalence and Pathogen Distribution

Culture positivity rates in suspected UTIs vary widely (10-65%), influenced by setting (community vs. hospital) and patient demographics. Females consistently show higher rates (2:1 or more compared to males. *E. coli* is the leading uropathogen nationwide, accounting for 50-70% of isolates, followed by *K. pneumoniae* (15-25%), *P. aeruginosa* (5-15%), and others, including *Proteus*, *Enterococcus*, and *Staphylococcus* species. Fungal isolates (*Candida* spp.) are rising, especially in hospitalized patients.

Table 1: Common Uropathogens in Indian UTI Studies

Pathogen	Prevalence Range (%)	Common in Community/Hospital
Escherichia coli	50-70	Both (predominant)
Klebsiella pneumoniae	15-25	Both
Pseudomonas aeruginosa	5-15	More hospital
Enterococcus spp.	5-10	Both
Others (*Proteus*, *Staph*)	<10	Variable

(Data synthesized from multiple Indian studies, e.g., central and western regions.26)

Antibiotic Resistance Patterns

Resistance to commonly used empirical antibiotics is alarmingly high. Third-generation cephalosporins show 70-80% resistance in *E. coli* and *K. pneumoniae*. Fluoroquinolones (e.g., ciprofloxacin) and cotrimoxazole often exceed 60-80% resistance. Carbapenem resistance is particularly concerning, crossing 20% even in community isolates for key Enterobacteriaceae. 226

ESBL production is a major driver, affecting 30-60% of isolates, leading to co-resistance to multiple classes. Colistin and aminoglycoside resistance, though lower, is emerging. Gram-positive organisms sh-

ow notable methicillin and vancomycin resistance in some cohorts.

Table 2: Antibiotic Resistance Rates (%) for Major Uropathogens in Recent Indian Studies

Antibiotic Class / Agent	***E. coli***	***K. pneumoniae***	***P. Aeruginosa***	***Notes (randomly)***
Ampicillin / Amoxicillin	80-90	80-95	High (not defined)	Near universal in many areas
Ciprofloxacin / Fluoroquinolones	60-80	60-80	70-85	High community resistance
3rd Gen Cephalosporins	70-80	65-75	Variable	ESBL-driven
Carbapenems	15-25	20-35	50-65	Rising in the community
Nitrofurantoin	15-25	Variable	Low activity	Relatively preserved
Amikacin / Gentamicin	15-30	20-50	30-60	Better option for GNB
Colistin	<10	5-15	<5	Reserve agent; emerging resistance



TREND OF RESISTANCE FROM 2020 TO 2025					
Pathogen	**2020**	**2021**	**2022**	**2023**	**2024–25**
E.coli-Ciprofloxacin	30%	↑	30–50%	40–60%	40–60%
E.coli- ESBL	20–40%	↑	↑	30–50%	30–50%+
Klebsiella-Carbapenem	Hospital	↑	↑	CRKP ↑	CRKP
Enterococcus-VRE	Single-digit	↑	↑	Upward	Rising
Pseudomonas-Carbapenem	Variable	↑	Variable	Variable	High
Nitrofurantoin	Preserved	Preserved	Preserved	Preserved	Effective

(Synthesized from surveillance data in central, western, and eastern India. Percentages are approximate ranges; local antibiograms are essential.)

Discussion

The data underscore a critical AMR crisis in Indian UTIs. Overuse of broad-spectrum antibiotics in outpatient and rural settings fuels selection pressure. Community-level carbapenem resistance (>20% in some reports) is especially worrisome, signaling potential treatment failures with standard regimens.226 ESBL and other mechanisms facilitate horizontal gene transfer, exacerbating spread.

Compared to global trends, Indian rates often surpass those in high-resource settings, highlighting gaps in stewardship. Females of reproductive age and elderly males bear a disproportionate burden, aligning with anatomical and comorbidity patterns. Rising *Candida* infections reflect antibiotic-driven dysbiosis.6

Limitations of existing data include heterogeneity in sampling, a lack of nationwide standardized surveillance, and underrepresentation of rural areas. Molecular studies on resistance genes (e.g., blaCTX-M, blaNDM) are increasing but fragmented.

Recommendations

1. Implement local antibiogram-guided empirical therapy (e.g., nitrofurantoin or fosfomycin for uncomplicated cystitis where susceptibility allows).
2. Strengthen antimicrobial stewardship programs (ASPs) with culture-directed treatment.
3. Promote infection prevention: hygiene, vaccination research (e.g., against uropathogenic *E. coli*), and regulated antibiotic access.
4. Invest in rapid diagnostics and genomic surveillance for real-time tracking.
5. Policy integration with national AMR action plans, emphasizing One Health approaches.

Conclusion

Antibiotic resistance in UTIs in India is a pressing public health challenge driven by prevalent Gram-negative pathogens and high MDR/ESBL rates. Preserving last-resort antibiotics requires immediate, multifaceted action. Future research should priorities prospective, multicenter studies with molecular characterization to guide precision medicine. Addressing this will reduce morbidity, healthcare costs, and the risk of untreatable infections.

References

1. Mohapatra S, et al. Prevalence and resistance pattern of uropathogens from community-acquired urinary tract infections in a tertiary care hospital in eastern India. *Cureus*. 2022. PMC8941965.0
2. Antimicrobial Resistance Trends in Urinary Tract Infection at Secondary Care Centers in Central India. *Gavin Publishers*. Recent data on carbapenem resistance.2
3. Parmar DV, et al. Antibacterial Resistance Trend in Urinary Tract Infections and Their Control at a Tertiary Care Hospital in the Saurashtra Region of Gujarat, India. *Biotechnol J Asia*. 2020.6
4. Gupta S, et al. Comparative Prevalence of Antimicrobial Resistance in Community-Acquired Urinary Tract Infection Cases from Representative States of Northern and Southern India. *J Glob Infect Dis*. 2014. PMC4225884.33
5. Sharma P, et al. Prevalence and in vitro antibiotic susceptibility pattern of bacterial isolates from tribal women suffering from urinary tract infection in central India. *Biomed Res Ther*. 2020.9
6. Gupta D, et al. Prevalence, Determinants, and Antibiotic Resistance Patterns of Urinary Tract Infection among Pregnant Women. *Indian J Community Med*. 2025.8
7. Chandrakumar S, et al. Sensitivity and resistance pattern of uropathogens causing urinary tract infections. PMC12858138. 2025.24
8. Kumar N, et al. Increased Isolation of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli from Community-Onset Urinary Tract Infection Cases in Uttarakhand, India. *Cureus*. 2021.20
9. Gharavi MJ, et al. Comprehensive study of antimicrobial susceptibility pattern of Escherichia coli isolates from urine samples. *Sci Rep*. 2021.22
10. Prakash D, et al. Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut. *J Glob Infect Dis*. 2013. PMC3830820.34
11. Dash M, et al. Antimicrobial resistance in pathogens causing urinary tract infections in a rural community of Odisha, India. *J Infect Dev Ctries*. 2013.37
12. Additional supporting studies on ESBL and regional patterns from Frontiers, Springer, and PMC sources (2022-2025).
13. Vignesh, N. V. V. a. D. K. M. J. S. G. V. (2026). A Review on Current Antibiotic Resistance Trends of Uropathogens in India, A Survey from Urology Department 2020 – 2025. Open MIND. https://doi.org/10.5281/zenodo.18479353